Five Reasons Celgene Could Gain 20%

RBC Capital Markets analyst Michael Yee and team explain why they think Celgene (CELG) is heading higher into 2015: 1. We think Celgene will go higher because Phase II Crohn’s data in October will look much better than Humira, plus it’s in oral form…we have a GED-0301 model and APP supporting $1B peak base-case and [...]